Formulation Sample Clauses
The 'Formulation' clause defines the process and standards by which a product, compound, or solution is created or composed within the scope of an agreement. It typically outlines the specific ingredients, proportions, and methods to be used, ensuring that the resulting formulation meets agreed-upon specifications or regulatory requirements. This clause is essential for maintaining consistency and quality in the final product, and it helps prevent disputes by clearly establishing how the formulation should be prepared and what standards must be met.
POPULAR SAMPLE Copied 2 times
Formulation. The formulation of BL-1040 is shown in Table 5.1.
Formulation. Prior to commencement of the 2-DAA Phase 2 Trial, Idenix shall use commercially reasonable efforts to formulate the Idenix Compound into either (1) a stable and feasible liquid formulation, or (2) a solid dosage formulation that can be bridged to the liquid formulation mentioned in (1) with a bioavailability study, without requiring to repeat the 2-DAA Phase 2 Trial.
Formulation. The Annual Performance Bonus will be determined from Employer's earnings before state and federal taxes ("Before Tax Earnings"). The Board shall each year during the term of this Agreement establish a Performance Bonus Criteria (herein so called) which shall be Employer's budgeted Before Tax Earnings for that year and which shall not be less than the Performance Bonus Criteria for the immediately preceding year.
(a) If Before Tax Earnings are less than 80% of Performance Bonus Criteria, Employee shall earn no Annual Performance Bonus. If Before Tax Earnings are equal to at least 80% of the Performance Bonus Criteria, Employee shall earn an 6 Annual Performance Bonus as determined under Paragraphs 5(B)(1)(b), (c) and (d) below, as applicable.
(b) If Before Tax Earnings are 80%-99% of the Performance Criteria, Employee shall earn an Annual Performance Bonus in an amount ranging between 25% and 48.75 % of Employee's Base Salary, determined on a prorated basis. For example, if Before Tax Earnings are 92% of the Performance Bonus Criteria, Employee shall earn an Annual Performance Bonus equal to 40% of Employee's Base Salary.
(c) If Before Tax Earnings are 100%-119% of the Performance Criteria, Employee shall earn an Annual Performance Bonus in an amount ranging between 50% and 97.5% of Employee's Base Salary, determined on a prorated basis. For example, if Before Tax Earnings are 110% of the Performance Criteria, Employee shall earn an Annual Performance Bonus equal to 75% of Employee's Base Salary.
(d) If Before Tax Earnings are 120% or greater of the Performance Bonus Criteria, Employee shall earn an Annual Performance Bonus equal to 100% of Employee's Base Salary, plus an additional 2% of Employee's Base Salary for each 1% above 120% of the Performance Bonus Criteria.
Formulation. The term "Formulation" is defined in Section 3.01(i) below.
Formulation. AstraZeneca will be responsible for conducting and paying for all formulation work to conduct the Amendment-Additional Collaboration Target Program. If requested by AstraZeneca, during the Amendment-Additional Collaboration Term Isis will provide reasonable assistance to AstraZeneca for such work as set out in the Amendment-Additional Collaboration Target Research and Development Plan. Isis will provide such assistance on an hourly basis [***] up to a reasonable maximum number of hours set by the Amendment-Additional Collaboration Target Working Group for each year of the Amendment-Additional Collaboration Term, and thereafter at Isis’ then current FTE Rate. AstraZeneca will resupply any finished Product necessary to support any Isis Conducted Activities, AstraZeneca Conducted Activities, IND toxicology studies and the Phase 1 Study for the Amendment-Additional Collaboration Target Program.
Formulation. Genentech and/or its Affiliates or sublicensee(s) shall be responsible for formulating such Genentech Products and shall bear all associated costs.
Formulation. Genentech and/or its sublicensee(s) shall be responsible for formulating such Lead Products and shall bear all associated costs.
Formulation. Renovis and/or its sublicensee(s) shall be responsible for formulating such Renovis Products and shall bear all associated costs.
Formulation. Both ricolinostat and placebo are liquid formulations to be administered orally in the morning. Each bottle of ricolinostat contains 12 mL of a 10 mg/mL solution. Placebo consists of the same liquid formulation, excluding the active ingredient (i.e., ricolinostat). Bitrex® is used in the placebo formulation to mimic the bitter taste of the active ingredient.
Formulation. For a period of one year from the Effective Date, Monsanto will order and purchase from Landec under the terms and conditions stated in this Section 4 its total requirement of Formulation and Landec will, under the terms and conditions stated in this Section 4, manufacture and sell to Monsanto an amount of Formulation equal to such total requirement and be responsible for the coating of seeds. At any time after the first anniversary of the Effective Date and during the Term, Monsanto has the option to (a) continue to order Formulation from Landec or (b) take over all manufacturing and production of Formulation and coating of seeds. The Parties agree that upon Monsanto’s request and at Monsanto’s sole expense, Landec will assist Monsanto in the transfer of manufacturing and production of Formulation and coating of seeds from Landec to Monsanto in order to allow Monsanto to commence commercial production of Formulation at any time specified by Monsanto on or after such first anniversary. If so requested by Monsanto, Landec will sell to Monsanto any equipment required by Monsanto for such manufacturing and production which is no longer required by Landec, at a purchase price equal to the fair market value thereof.